Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.

Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew A Parsons, Barone FC.

Exp Neurol. 2008 Jul;212(1):53-62. doi: 10.1016/j.expneurol.2008.03.011. Epub 2008 Mar 25.

PMID:
18462720
3.

p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 2. Improved renal function as assessed by dynamic contrast-enhanced magnetic resonance imaging.

Lenhard SC, Nerurkar SS, Schaeffer TR, Mirabile RC, Boyce RW, Adams DF, Jucker BM, Willette RN.

J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. Epub 2003 Oct 15.

PMID:
14561850
4.

Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study.

Jucker BM, Schaeffer TR, Haimbach RE, Mayer ME, Ohlstein DH, Smith SA, Cobitz AR, Sarkar SK.

Metabolism. 2003 Feb;52(2):218-25.

PMID:
12601636
5.

Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study.

Jucker BM, Schaeffer TR, Haimbach RE, McIntosh TS, Chun D, Mayer M, Ohlstein DH, Davis HM, Smith SA, Cobitz AR, Sarkar SK.

Diabetes. 2002 Jul;51(7):2066-73.

6.

Acute stroke therapy: translating preclinical neuroprotection to therapeutic reality.

Parsons AA, Irving EA, Legos JJ, Lenhard SC, Chandra S, Schaeffer TR, Haimbach RE, White RF, Hunter AJ, Barone FC.

Curr Opin Investig Drugs. 2000 Dec;1(4):452-63. Review. No abstract available.

PMID:
11249699
7.

Effects of omapatrilat in low, normal, and high renin experimental hypertension.

Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR.

Am J Hypertens. 1998 Mar;11(3 Pt 1):363-72.

PMID:
9544878
8.

Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.

Robl JA, Sun CQ, Stevenson J, Ryono DE, Simpkins LM, Cimarusti MP, Dejneka T, Slusarchyk WA, Chao S, Stratton L, Misra RN, Bednarz MS, Asaad MM, Cheung HS, Abboa-Offei BE, Smith PL, Mathers PD, Fox M, Schaeffer TR, Seymour AA, Trippodo NC.

J Med Chem. 1997 May 23;40(11):1570-7.

PMID:
9171867
9.

Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.

Robl JA, Cimarusti MP, Simpkins LM, Brown B, Ryono DE, Bird JE, Asaad MM, Schaeffer TR, Trippodo NC.

J Med Chem. 1996 Jan 19;39(2):494-502.

PMID:
8558518
10.

Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.

Trippodo NC, Robl JA, Asaad MM, Bird JE, Panchal BC, Schaeffer TR, Fox M, Giancarli MR, Cheung HS.

J Pharmacol Exp Ther. 1995 Nov;275(2):745-52.

PMID:
7473162
11.

Quinoxaline N-oxide containing potent angiotensin II receptor antagonists: synthesis, biological properties, and structure-activity relationships.

Kim KS, Qian L, Bird JE, Dickinson KE, Moreland S, Schaeffer TR, Waldron TL, Delaney CL, Weller HN, Miller AV.

J Med Chem. 1993 Aug 6;36(16):2335-42.

PMID:
8360878
12.

Antihypertensive activity in rats for SQ 14,225, an orally active inhibitor of angiotensin I-converting enzyme.

Laffan RJ, Goldberg ME, High JP, Schaeffer TR, Waugh MH, Rubin B.

J Pharmacol Exp Ther. 1978 Feb;204(2):281-8.

PMID:
202693
13.

Inhibition by SQ 20881 of vasopressor response to angiotensin I in conscious animals.

Bianchi A, Evans DB, Cobb M, Peschka MT, Schaeffer TR, Laffan RJ.

Eur J Pharmacol. 1973 Jul;23(1):90-6. No abstract available.

PMID:
4354808
14.

Effects of the nonapeptide SQ 20881 on blood pressure of rats with experimental renovascular hypertension.

Engel SL, Schaeffer TR, Waugh MH, Rubin B.

Proc Soc Exp Biol Med. 1973 Jun;143(2):483-7. No abstract available.

PMID:
4709014
15.

Inhibition of pressor effects of angiotensin I and augmentation of depressor effects of bradykinin by synthetic peptides.

Engel SL, Schaeffer TR, Gold BI, Rubin B.

Proc Soc Exp Biol Med. 1972 May;140(1):240-4. No abstract available.

PMID:
4338183

Supplemental Content

Loading ...
Support Center